Back to search results
NCT03662776

Effect of Treatment Modality on Psychosocial Functioning of Survivors of Unilateral Retinoblastoma

Enrolling by Invitation
Not specifiedAges 8–17Observational
Memorial Sloan Kettering Cancer Center
~120 participants
Updated 2025-09-03 on ClinicalTrials.gov
What's tested:BASC-3 surveyPROMIS survey

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
social-emotional health
Measured over 2 years
+2 more outcomes measured

Conditions

Survivors of Unilateral Retinoblastoma

Explore related trials

Retinoblastoma

Where it's being run

2 sites across 2 states
New York1
Texas1

Study leadership

  • Laura Cimini, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to speak and understand English or Spanish
Diagnosis of unilateral retinoblastoma at any age, confirmed by the enrolling institution
Treatment of retinoblastoma between 2006 or later
Patients must between the age of 8-17 years old
At least 1 year since completion of all cancer-directed therapy
Treatment with enucleation of the affected eye or intra-arterial chemotherapy
Ability to speak and understand English or Spanish
Ability to confirm that he or she is the parent of a child treated for unilateral retinoblastoma who meets the eligibility criteria listed above
Ability to provide informed consent

Exclusion

Patients, or parents of patients, treated with both enucleation and intra-arterial chemotherapy are not eligible

What this trial measures

  • social-emotional health2 years

    as measured by Behavior Assessment System for Children, 3rd edition, (BASC™-3;as measured by the BASC-3) Surveys have been normed on a representative sample that closely matches United States census population characteristics; T scores and percentiles in relation to general norms are calculated for each scale. The BASC-3 uses a T score metric where 50 is the mean for the population norm and the standard deviation is 10.

  • behavioral health2 year

    as measured by Behavior Assessment System for Children, 3rd edition, (BASC™-3; The following four T Scores will be analyzed for these BASC-3 summary scores (1) Externalizing Problems, (2) Internalizing Problems, (3) Behavior Symptoms Index and (4) Adaptive Skills. The "at-risk" category applies to any individual who scores 2 SD above the mean of 50, while "clinically significant" risk refers to those who score 3 SD above the mean. Additional scores are also provided which may be used to identify risk for more specific behavioral or emotional areas of concern.

  • compare HRQoL2 years

    as measured by the Patient Reported Outcomes Measurement Information System (PROMIS®) PROMIS measures use a T-score metric where 50 is the mean for the reference population and 10 is the standard deviation of that population. Higher scores correspond to a higher degree of symptom burden (for those items measuring symptoms) or a higher level of functioning (for physical functioning items)